Article
BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature.
The Journal of investigative dermatology - 1 Jul 2023
Gaubert Alexandre, Kervarrec Thibault, Montaudié Henri, Burel-Vandenbos Fanny, Cardot-Leccia Nathalie, Di Mauro Ilaria, Fabas Thibault, Tallet Anne, Kubiniek Valérie, Pedeutour Florence, Dadone-Montaudié Bérengère
Abstract excerpt
Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine cancer. Management of advanced MCC is mainly based on immune-checkpoint inhibitors. The high failure rate warrants an investigation of new therapeutic targets. The recent identification of BRCA1 or BRCA2 (BRCA1/2) mutations in some MCC raises the issue of the use of poly-(ADP-Ribose)-polymerase inhibitors in selected advanced cases. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.